AAAAAA

   
Results: 1-11 |
Results: 11
IMPACT OF DONOR LYMPHOCYTE INFUSION FOR HEMATOLOGICAL MALIGNANCY RELAPSED AFTER ALLOGENEIC BONE-MARROW TRANSPLANTATION
Authors: ZEDER K WALLER EK REDEI I CONNAGHAN DG FLEMING WH GELLER RB HEFFNER LT HILLYER CD HOLDEN J HOLLAND K JONES W MCCOLLUM J MOGUL M PHILLIPS C RODEY G WINGARD JR WINTON E YEAGER AM DEVINE S
Citation: K. Zeder et al., IMPACT OF DONOR LYMPHOCYTE INFUSION FOR HEMATOLOGICAL MALIGNANCY RELAPSED AFTER ALLOGENEIC BONE-MARROW TRANSPLANTATION, Cancer research, therapy & control, 5(4), 1998, pp. 221-228
ALLOGENEIC BONE-MARROW TRANSPLANTATION WITH MATCHED UNRELATED DONORS FOR PATIENTS WITH HEMATOLOGIC MALIGNANCIES USING A PREPARATIVE REGIMENOF HIGH-DOSE CYCLOPHOSPHAMIDE AND FRACTIONATED TOTAL-BODY IRRADIATION
Authors: GELLER RB DEVINE SM OTOOLE K PERSONS L KELLER J MAUER D HOLLAND HK DIX SP PIOTTI M REDEI I CONNAGHAN G HEFFNER LT HILLYER CD WALLER EK WINTON EF WINGARD JR
Citation: Rb. Geller et al., ALLOGENEIC BONE-MARROW TRANSPLANTATION WITH MATCHED UNRELATED DONORS FOR PATIENTS WITH HEMATOLOGIC MALIGNANCIES USING A PREPARATIVE REGIMENOF HIGH-DOSE CYCLOPHOSPHAMIDE AND FRACTIONATED TOTAL-BODY IRRADIATION, Bone marrow transplantation, 20(3), 1997, pp. 219-225
DETECTION OF A DORMANT 20Q- LEUKEMIA CLONE IN BONE-MARROW CULTURES WITH HEMATOPOIETIC GROWTH-FACTORS - IMPLICATIONS FOR SECONDARY LEUKEMIA POSTTRANSPLANT
Authors: REDEI I MANGAN KF MING PL MULLANEY MT RAO PN GOLDBERG SL KLUMPP TR
Citation: I. Redei et al., DETECTION OF A DORMANT 20Q- LEUKEMIA CLONE IN BONE-MARROW CULTURES WITH HEMATOPOIETIC GROWTH-FACTORS - IMPLICATIONS FOR SECONDARY LEUKEMIA POSTTRANSPLANT, Bone marrow transplantation, 19(5), 1997, pp. 521-523
SUCCESSFUL ENGRAFTMENT AFTER PRIMARY GRAFT FAILURE IN APLASTIC-ANEMIAUSING G-CSF MOBILIZED PERIPHERAL STEM-CELL TRANSFUSIONS
Authors: REDEI I WALLER EK HOLLAND HK DEVINE SM WINGARD JR
Citation: I. Redei et al., SUCCESSFUL ENGRAFTMENT AFTER PRIMARY GRAFT FAILURE IN APLASTIC-ANEMIAUSING G-CSF MOBILIZED PERIPHERAL STEM-CELL TRANSFUSIONS, Bone marrow transplantation, 19(2), 1997, pp. 175-177
THE NUMBER OF CD34- CELLS IN THE GRAFT PREDICTS THE KINETICS OF HEMATOPOIETIC RECONSTITUTION FOLLOWING AUTOLOGOUS OR ALLOGENEIC BONE-MARROWTRANSPLANTATION (BMT)(, CD38)
Authors: WALLER EK LYNN M WORFORD L WINTON EF REDEI I HEFFNER T HILLYER CD SMITH K BUCUR S LOPEZ R BRAY RA JONES W ROSENTHAL H MCCOLLUM J YEAGER AM
Citation: Ek. Waller et al., THE NUMBER OF CD34- CELLS IN THE GRAFT PREDICTS THE KINETICS OF HEMATOPOIETIC RECONSTITUTION FOLLOWING AUTOLOGOUS OR ALLOGENEIC BONE-MARROWTRANSPLANTATION (BMT)(, CD38), Blood, 90(10), 1997, pp. 1753-1753
7.5 GY IRRADIATION ATTENUATES THE GRAFT-VS-HOST DISEASE (GVHD) POTENTIAL OF ALLOGENEIC LYMPHOCYTES WHILE PRESERVING ANTILEUKEMIC ACTIVITY IN PRECLINICAL AND CLINICAL-STUDIES
Authors: WALLER EK REDEI I YEAGER AM WINTON EF HEFFNER T HILLYER CD CARTER R SMITH K HOLLAND HK CONNAGHAN G PHILLIPS C HOLDEN JT GUERRIERO A MURRAY T WORFORD L JURICKOVA I BOYER M
Citation: Ek. Waller et al., 7.5 GY IRRADIATION ATTENUATES THE GRAFT-VS-HOST DISEASE (GVHD) POTENTIAL OF ALLOGENEIC LYMPHOCYTES WHILE PRESERVING ANTILEUKEMIC ACTIVITY IN PRECLINICAL AND CLINICAL-STUDIES, Blood, 90(10), 1997, pp. 2437-2437
TREATMENT OF HEPATIC VENOOCCLUSIVE DISEASE WITH LOW-DOSE TISSUE-PLASMINOGEN ACTIVATOR - IMPACT ON COAGULATION PROFILE
Authors: GOLDBERG SL SHUBERT J RAO AK REDEI I KLUMPP TR MANGAN KF
Citation: Sl. Goldberg et al., TREATMENT OF HEPATIC VENOOCCLUSIVE DISEASE WITH LOW-DOSE TISSUE-PLASMINOGEN ACTIVATOR - IMPACT ON COAGULATION PROFILE, Bone marrow transplantation, 18(3), 1996, pp. 633-636
FEASIBILITY OF 2ND MYELOABLATIVE THERAPY FOLLOWED BY MATCHED UNRELATED DONOR (MUD) TRANSPLANT FOR PATIENTS WITH HEMATOLOGIC MALIGNANCIES WHO RELAPSE AFTER AUTOLOGOUS BONE-MARROW TRANSPLANTATION (ABMT)
Authors: REDEI I GELLER RB OTOOLE K DEVINE S HOLLAND HK WINGARD JR YEAGER AM
Citation: I. Redei et al., FEASIBILITY OF 2ND MYELOABLATIVE THERAPY FOLLOWED BY MATCHED UNRELATED DONOR (MUD) TRANSPLANT FOR PATIENTS WITH HEMATOLOGIC MALIGNANCIES WHO RELAPSE AFTER AUTOLOGOUS BONE-MARROW TRANSPLANTATION (ABMT), Blood, 88(10), 1996, pp. 3846-3846
PHASE-II TRIAL OF TOPOTECAN IN ADVANCED OR METASTATIC ADENOCARCINOMA OF THE PANCREAS
Authors: SCHER RM KOSIEROWSKI R LUSCH C ALEXANDER R FOX S REDEI I GREEN F RASKAY B AMFOH K ENGSTROM PF ODWYER PJ
Citation: Rm. Scher et al., PHASE-II TRIAL OF TOPOTECAN IN ADVANCED OR METASTATIC ADENOCARCINOMA OF THE PANCREAS, Investigational new drugs, 13(4), 1995, pp. 347-354
PHASE-II TRIAL OF PALA AND 6-METHYLMERCAPTOPURINE RIBOSIDE (MMPR) IN COMBINATION WITH 5-FLUOROURACIL IN ADVANCED PANCREATIC-CANCER
Authors: REDEI I GREEN F HOFFMAN JP WEINER LM SCHER R ODWYER PJ
Citation: I. Redei et al., PHASE-II TRIAL OF PALA AND 6-METHYLMERCAPTOPURINE RIBOSIDE (MMPR) IN COMBINATION WITH 5-FLUOROURACIL IN ADVANCED PANCREATIC-CANCER, Investigational new drugs, 12(4), 1994, pp. 319-321
COAGULATION PARAMETERS DURING SUCCESSFUL TREATMENT OF HEPATIC VENOOCCLUSIVE DISEASE (VOD) WITH LOW-DOSE TISSUE-PLASMINOGEN ACTIVATOR (T-PA)
Authors: GOLDBERG SL REDEI I WALSH PN RAO AK KLUMPP TR MANGAN KF
Citation: Sl. Goldberg et al., COAGULATION PARAMETERS DURING SUCCESSFUL TREATMENT OF HEPATIC VENOOCCLUSIVE DISEASE (VOD) WITH LOW-DOSE TISSUE-PLASMINOGEN ACTIVATOR (T-PA), Blood, 84(10), 1994, pp. 10000488-10000488
Risultati: 1-11 |